
Infectious disease readiness depends on rehearsed workflows, bidirectional public health communication, and rapid access to care.
Cancidas, previously approved for use in adults, can now be applied also to pediatric patients aged three months to 17 years.
Merck's Cancidas (caspofungin acetate), previously approved for use in adults, can now be applied also to pediatric patients aged three months to 17 years. The Whitehouse Station, N.J., firm claims that the approval makes
To see more Daily News articles,
To go to the Drug Topics homepage,






